

Obizur® (Antihemophilic Factor [Recombinant], Porcine Sequence)

When requesting Obizur® (Antihemophilic Factor [Recombinant], Porcine Sequence), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indications.

FDA-Approved indication

Obizur is an antihemophilic factor (porcine sequence) indicated for the on-demand treatment and control of bleeding episodes in adults with acquired hemophilia A.

Coverage Guidelines

Acquired Hemophilia A

- The request is for treatment or prevention of bleeding episodes in individuals with acquired hemophilia A; AND
- The individual is 18 years of age or older; AND
- Obizur is prescribed by or in consultation with a hemophilia specialist.

Approval duration: 12 months

Dosing Recommendations

Obizur

The recommended initial dose is 200 units/kg. Titrate dose and frequency of administration based on factor VIII recovery levels and individual clinical response.

References

1. Obizur prescribing information. Westlake Village, CA; Baxalta US Inc. December 2024.
2. National Hemophilia Foundation for all bleeding disorders. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. MASAC Document #263. Revised September 2020.
3. World Federation of Hemophilia. WFH Guidelines for the Management of Hemophilia. 3rd edition. Haemophilia.2020;00:1-158.
4. Antihemophilic Factor (Recombinant). Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. [Updated; April 15, 2024; Accessed April 23, 2024].
5. National hemophilia Foundation for all bleeding disorders. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Selected Disorders of the Coagulation System. MASAC Document #276. Revised May 2023.
6. Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021;397:630-640.

7. Croteau SE. Hemophilia A/B. Hematol Oncol Clin North Am. 2022;36(4):797-812.
8. Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost. 2022;48(8):904-910.
9. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments and its complications. Lancet. 2016;388(10040):187-197.
10. National Bleeding Disorders Foundation. MASAC (Medical and Scientific Advisory Council) recommendations concerning products licensed for the treatment of hemophilia and selected disorders of the coagulation system (endorsed October 2, 2025). MASAC Document #290. Available at: <https://www.hemophilia.org/sites/default/files/document/files/MASAC-Products-Licensed.pdf>. Accessed on February 17, 2025.
11. National Hemophilia Foundation. MASAC (Medical and Scientific Advisory Council) recommendations regarding doses of clotting factor concentrate in the home (Revised June 7, 2016). MASAC Document #242. Adopted on September 3, 2020. Available at: <https://www.hemophilia.org/sites/default/files/document/files/242.pdf>. Accessed on February 19, 2025.